SAB Biotherapeutics Commences Underwritten Public Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy SABS?
SAB Biotherapeutics announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the proposed offering are to be sold by SAB BIO. The company intends to use the net proceeds it receives from this offering, together with its existing cash, cash equivalents and marketable securities, primarily to fund the continued development of our clinical stage product candidate, SAB-142 through ongoing and planned clinical trials, as well as for related manufacturing, regulatory, and operational activities, and for working capital and general corporate purposes. Jefferies, UBS Investment Bank, Citigroup, and Barclays are acting as joint book-running managers for the offering. Chardan is acting as lead manager.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SABS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SABS
Wall Street analysts forecast SABS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.530
Low
7.00
Averages
10.33
High
15.00
Current: 3.530
Low
7.00
Averages
10.33
High
15.00
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
- Significant Agreement Value: Emergent BioSolutions has signed a multi-year agreement valued at approximately $50 million with SAB Biotherapeutics, of which $36 million is contingent on future regulatory approvals and milestones, reflecting both companies' confidence in advancing drug development.
- Comprehensive Manufacturing Services: Under the agreement, Emergent will provide end-to-end development and manufacturing services compliant with current good manufacturing practices, including process development, technology transfer, and clinical and commercial manufacturing for SAB-142, ensuring product quality and compliance.
- Facility Advantage: Emergent's Winnipeg manufacturing facility, recognized for its expertise in plasma-derived and complex biologics, has been selected as the primary site for the development and production of SAB-142, enhancing production efficiency and accelerating clinical timelines.
- Deepening Strategic Collaboration: This partnership not only highlights Emergent's manufacturing capabilities in the biopharmaceutical sector but also underscores SAB BIO's innovative potential in treating autoimmune type 1 diabetes, which could transform the treatment landscape for this condition.
See More
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
- Significant Agreement Value: Emergent BioSolutions has signed a multi-year agreement with SAB Biotherapeutics valued at approximately $50 million, with $36 million contingent on future regulatory approvals and milestones, indicating strong confidence in the project's success.
- Enhanced Manufacturing Capabilities: Under the agreement, Emergent will provide end-to-end development and manufacturing services compliant with current good manufacturing practices at its Winnipeg facility, ensuring smooth progress for SAB-142's clinical program and future commercial production.
- Technology Transfer and Scale-Up: The agreement includes services for process development and analytical method transfer, which will accelerate the clinical progression of SAB-142, potentially offering new treatment options for diabetes patients and holding significant market potential.
- Strategic Partnership: This collaboration not only showcases Emergent's expertise in the biopharmaceutical sector but also reflects SAB BIO's commitment to developing innovative therapies for autoimmune diabetes, with their partnership poised to advance the commercialization of new therapies.
See More
SAB Bio Reveals New Clinical and Mechanistic Findings from SAB-142 Phase 1 Trial in Adults with Established Autoimmune Type 1 Diabetes at IDS 2026
Clinical Trial Announcement: SAB Biotherapeutics has presented additional clinical and mechanistic data from its SAB-142 Phase 1 trial.
Target Patient Group: The trial focuses on adult patients with established Type 1 diabetes.
See More
SAB Biotherapeutics Completes $85M Stock Offering
- Offering Size: SAB Biotherapeutics priced approximately 19.32 million common shares at $3.85 each, raising a total of $85 million, indicating the company's proactive approach to securing funding.
- Clear Use of Proceeds: The net proceeds from this offering will primarily be allocated to advancing SAB-142 clinical trials, manufacturing, regulatory efforts, and operations, while also bolstering working capital to ensure sufficient funding during critical R&D phases.
- Underwriter's Option: The underwriters have a 30-day option to purchase an additional ~3.31 million shares, providing the company with flexibility for further financing, which could help address future capital needs.
- Market Reaction: Following the announcement of the stock offering, SAB Biotherapeutics' stock price dropped about 5% in after-hours trading on Tuesday, reflecting a cautious market sentiment that may impact investor confidence.
See More
SAB Biotherapeutics Launches Public Offering to Fund Diabetes Candidate
- Public Offering Initiated: SAB Biotherapeutics (SABS) has launched an underwritten public offering of common stock and pre-funded warrants, which is expected to provide significant funding support for the company.
- Additional Securities Option: The offering includes an option for underwriters to purchase up to 15% additional securities within 30 days, a flexibility that may attract more investor participation.
- Clear Use of Proceeds: Proceeds from the offering will primarily support the development of its lead candidate SAB-142 for Type 1 Diabetes, while also covering clinical trials, manufacturing, regulatory activities, and general corporate expenses, ensuring smooth project advancement.
- Negative Market Reaction: Following the public offering announcement, SABS shares fell 6.9% in after-hours trading, reflecting market caution regarding the financing, which may impact the company's future fundraising capabilities.
See More
SAB Biotherapeutics Reports Positive Phase 1 Data for SAB-142 in T1D
- C-Peptide Preservation: In a cohort of six T1D patients, four treated with SAB-142 showed no decrease in C-peptide levels at Day 120, indicating potential efficacy that could transform T1D treatment paradigms.
- Clinical Trial Design: The Phase 1 trial utilized a randomized, double-blind, placebo-controlled design aimed at assessing the safety and pharmacodynamics of SAB-142, establishing a foundation for the subsequent Phase 2b trial, with topline data expected in the second half of 2027.
- Biomarker Support: Preliminary data indicate that biomarkers of T cell exhaustion align with preserved C-peptide levels, enhancing confidence in SAB-142's mechanism of action and potentially offering new treatment options for patients.
- Market Potential: As a potential disease-modifying therapy, SAB-142 could change the treatment landscape for T1D, addressing the urgent need for novel therapies among patients and further driving the company's growth in the biopharmaceutical sector.
See More
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
- Significant Agreement Value: Emergent BioSolutions has signed a multi-year agreement valued at approximately $50 million with SAB Biotherapeutics, of which $36 million is contingent on future regulatory approvals and milestones, reflecting both companies' confidence in advancing drug development.
- Comprehensive Manufacturing Services: Under the agreement, Emergent will provide end-to-end development and manufacturing services compliant with current good manufacturing practices, including process development, technology transfer, and clinical and commercial manufacturing for SAB-142, ensuring product quality and compliance.
- Facility Advantage: Emergent's Winnipeg manufacturing facility, recognized for its expertise in plasma-derived and complex biologics, has been selected as the primary site for the development and production of SAB-142, enhancing production efficiency and accelerating clinical timelines.
- Deepening Strategic Collaboration: This partnership not only highlights Emergent's manufacturing capabilities in the biopharmaceutical sector but also underscores SAB BIO's innovative potential in treating autoimmune type 1 diabetes, which could transform the treatment landscape for this condition.
See More
Emergent BioSolutions Signs $50 Million Agreement with SAB Biotherapeutics
- Significant Agreement Value: Emergent BioSolutions has signed a multi-year agreement with SAB Biotherapeutics valued at approximately $50 million, with $36 million contingent on future regulatory approvals and milestones, indicating strong confidence in the project's success.
- Enhanced Manufacturing Capabilities: Under the agreement, Emergent will provide end-to-end development and manufacturing services compliant with current good manufacturing practices at its Winnipeg facility, ensuring smooth progress for SAB-142's clinical program and future commercial production.
- Technology Transfer and Scale-Up: The agreement includes services for process development and analytical method transfer, which will accelerate the clinical progression of SAB-142, potentially offering new treatment options for diabetes patients and holding significant market potential.
- Strategic Partnership: This collaboration not only showcases Emergent's expertise in the biopharmaceutical sector but also reflects SAB BIO's commitment to developing innovative therapies for autoimmune diabetes, with their partnership poised to advance the commercialization of new therapies.
See More
SAB Bio Reveals New Clinical and Mechanistic Findings from SAB-142 Phase 1 Trial in Adults with Established Autoimmune Type 1 Diabetes at IDS 2026
Clinical Trial Announcement: SAB Biotherapeutics has presented additional clinical and mechanistic data from its SAB-142 Phase 1 trial.
Target Patient Group: The trial focuses on adult patients with established Type 1 diabetes.
See More
SAB Biotherapeutics Completes $85M Stock Offering
- Offering Size: SAB Biotherapeutics priced approximately 19.32 million common shares at $3.85 each, raising a total of $85 million, indicating the company's proactive approach to securing funding.
- Clear Use of Proceeds: The net proceeds from this offering will primarily be allocated to advancing SAB-142 clinical trials, manufacturing, regulatory efforts, and operations, while also bolstering working capital to ensure sufficient funding during critical R&D phases.
- Underwriter's Option: The underwriters have a 30-day option to purchase an additional ~3.31 million shares, providing the company with flexibility for further financing, which could help address future capital needs.
- Market Reaction: Following the announcement of the stock offering, SAB Biotherapeutics' stock price dropped about 5% in after-hours trading on Tuesday, reflecting a cautious market sentiment that may impact investor confidence.
See More
SAB Biotherapeutics Launches Public Offering to Fund Diabetes Candidate
- Public Offering Initiated: SAB Biotherapeutics (SABS) has launched an underwritten public offering of common stock and pre-funded warrants, which is expected to provide significant funding support for the company.
- Additional Securities Option: The offering includes an option for underwriters to purchase up to 15% additional securities within 30 days, a flexibility that may attract more investor participation.
- Clear Use of Proceeds: Proceeds from the offering will primarily support the development of its lead candidate SAB-142 for Type 1 Diabetes, while also covering clinical trials, manufacturing, regulatory activities, and general corporate expenses, ensuring smooth project advancement.
- Negative Market Reaction: Following the public offering announcement, SABS shares fell 6.9% in after-hours trading, reflecting market caution regarding the financing, which may impact the company's future fundraising capabilities.
See More
SAB Biotherapeutics Reports Positive Phase 1 Data for SAB-142 in T1D
- C-Peptide Preservation: In a cohort of six T1D patients, four treated with SAB-142 showed no decrease in C-peptide levels at Day 120, indicating potential efficacy that could transform T1D treatment paradigms.
- Clinical Trial Design: The Phase 1 trial utilized a randomized, double-blind, placebo-controlled design aimed at assessing the safety and pharmacodynamics of SAB-142, establishing a foundation for the subsequent Phase 2b trial, with topline data expected in the second half of 2027.
- Biomarker Support: Preliminary data indicate that biomarkers of T cell exhaustion align with preserved C-peptide levels, enhancing confidence in SAB-142's mechanism of action and potentially offering new treatment options for patients.
- Market Potential: As a potential disease-modifying therapy, SAB-142 could change the treatment landscape for T1D, addressing the urgent need for novel therapies among patients and further driving the company's growth in the biopharmaceutical sector.
See More
